George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
I’m signing off for the foreseeable future this game is hard enough to get your head around without games being played by significant holders. They say one thing and do the other. Today’s actions do not give personal investors confidence and are the exact opposite to what we as shareholders were told in an rns.
“The key drivers are all shareholders, who have had to become accustomed to the vagaries of the stock market and how it values the Company`s shares. Oftentimes the market capitalization of the Company has changed over a small number of trading days by 10-25% without any discernable reason”
“We believe that the cumulative accretion of value during this time is not adequately reflected in the current market valuation of the Company, and we are now considering how best to address this anomaly.”
Is this one of those “vagaries” or is it an “anomaly” it would be great if you could update the “ALL SHAREHOLDERS” on why we should buy your company shares while you and your family sell?
Picked up another 580k on the drop, thank you very much!!
Dr. Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology at MCW is the Chair and Co-principal investigator of the study and, along with Co-principal investigator Dr. Jennifer Connelly, MD, Associate Professor of Neurology at MCW, will be enrolling patients in the study. Both are long-standing collaborators with Kathleen Schmainda, PhD, a co-founder of IB and a recognised leader in brain tumour imaging. Together they have researched and developed the use of GaM in preclinical GBM trials. Since the advanced brain tumour imaging offered by IQAI is needed to monitor treatment efficacy for this trial, the investigators approached the Company as a natural partner to provide resources and expertise for this Phase 1 clinical trial.
From the first announcement about the trial
I was told recently. When they have something substantive to say they will and can’t say much more at present in regards to a question about an update on zero G.
This statement from the final results rns makes me think we are due an update soon on this. Probably submission of de novo application .
Using patented artificial intelligence ("AI") technology, IB Zero G generates enhanced "with contrast" images using only non-contrast (0% gadolinium) images as input. The FDA's response to the FDA 510(k) submission concluded that IB Zero G™ was too novel and unique a product and subsequently directed IB to pursue a different regulatory clearance pathway. IB is compiling additional documentation in preparation for a pre-submission meeting with the FDA and plans to submit a "de novo" application in the second half of the year. The de novo request is a market clearance pathway designed for novel medical devices for which no legally marketed predicate device exists to demonstrate substantial equivalence.
This is also from previous updates
In response to how well patients are tolerating the agent and to meet the goal of the phase 1, defining the MTD, the clinical team is preparing an amendment to the original study protocol. The amendment will expand the targeted enrolment from 24 to 36 subjects and allow for continued dose escalation. The MTD determined in Phase 1 will define the "recommended phase II dose" (RP2D) that will be used in the Phase 2 trial. This amendment is the fastest and most efficient way to satisfy the primary goal of the Phase 1.
Given the expanded target enrolment and assuming the strong momentum in patient enrolment continues, it is anticipated that Phase 1 will close in 2024. After enrolment closes, the last patients enrolled will remain on the trial until all required study data is collected. Analysing the data and documenting the phase 1 results is expected to be completed in the second half of 2024.
While the MTD is being determined in the final stages of Phase 1, the clinical team will complete the Phase 2 protocol. The Phase 2 trial is designed to evaluate preliminary evidence of efficacy. Ideally, the Phase II trial will open for patient recruitment in early 2025. This will be a multi-centre trial with a tentative target enrolment of approximately 65 patients over a three-year duration. The design of the Phase 2 study is currently being defined. Factors such as the Phase 1 results and whether the study will be a comparison to historical controls or if it will be randomized (comparing patients with standard treatment alone against those receiving standard treatment with GaM) will influence the overall scope and cost.
The multi-site Phase 2 trial will require new funding which we anticipate will come substantially from a partnership arrangement with a large pharmaceutical company and grants, including those from charitable foundations and other institutions. We anticipate publishing frequent updates to our shareholders as developments unfold.
It just says
Experimental: Dose-expansion Phase
A minimum of six participants will be enrolled in the dose expansion phase for a total of 12 subjects at the recommended phase 2 dose.
Drug: Gallium maltolate (recommended phase 2 dose)
The maximum-tolerated dose (recommended phase 2 dose).
Other Names:
CAS 108560-70-9
Hopefully means we will receive an update soon.
GLA!!
Again in another study, IB’s proprietary standardized rCBV (perfusion) technology in IB Neuro shows the best reproducibility/consistency compared to normalized rCBV available from other vendors. And, normalizing rCBV values requires manual input ... IB Neuro is fully automated
Twitter account in overdrive mode tonight!!
@IQAI_IB
's IB Neuro offers multiple exclusive features for MR perfusion, but it also automatically processes CT perfusion maps (including auto AIF detection). Front end intelligence determines the type of data to be processed (MR or CT) and executes the appropriate algorithm.
Nice pickup of the recently published study...
Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR
“The study demonstrates that a single dose (no preload), low flip angle method does not compromise image quality,” said Dr. Mark Shiroishi, MD. “This is a great added benefit for patients who may have concerns about GBCA risks, and for administrators looking for opportunities to curtail operational expenses”.
https://www.itnonline.com/content/reduced-gadolinium-approach-validated-ib-neuro-15t-mr-scanners
Shared by a client - another case showing how IB Delta T1 maps (patent-pending) and IB Neuro (quantitative rCBV) can impact treatment decisions.
Pre-surgical MRI shows a concerning lesion on T1+C.
Post-surgical pathological diagnosis = No tumor
IB Software = No tumor
https://twitter.com/IQAI_IB/status/1704965865752481974
Amrami says the most important objective of this research is to demonstrate, and raise awareness around, the clinical need for these solutions.
“The determination of what constitutes quality care and how to generalize that is an important question that has to be addressed through investigation and reliable data in terms of the impact of medical imaging and theranostics on improving patient outcomes,” she said.
GE HealthCare has embarked on a number of collaborations in both these areas. In August, it teamed up with Imaging Biometrics, a subsidiary of IQ-AI, agreeing to use its MR Smart Subscription solution to distribute IB Neuro and IB Delta T1 applications to more MR providers. These applications use MR brain imaging data to create quantitative, proprietary mapped images that streamline scan acquisitions, processing, and readings.
https://www.dotmed.com/news/story/61239
Nice to see us mentioned in this article
And yes added another 650k to the pile today can’t believe you can still buy pound coins for pennies!
GLA!!
Blackfords was acquired shortly after their collaboration with bayer IQAI have entered a collaboration with bayer and recently GE could we be about to see a cheeky bid to buy us out? If Trevor didn’t sell any of his holding at 20p and with all the positive news regarding the trial I wonder what could entice him
GLA!
The de novo request is a market clearance pathway designed for novel medical devices for which no legally marketed predicate device exists to demonstrate substantial equivalence. So we could receive an update on this imminently also.
#IQAI shares have previously traded as high as 24p and as low as 1p with all this recent positive news announced they could in my opinion be headed back to 20p+ although this time they have a dual listing on the us otc market so we could see new all time highs if it gets picked up over there with the us investors having deeper pockets. There are 183m shares in issue and the ceo holds 29% of these so it’s in his best interest for these to succeed. Currently shares are 3.8/4p giving a market capitalisation of £6.9m. With all these factors and with their footprint in the USA only getting bigger and deals being signed better this share will in my opinion be multiples of today’s price in the very near future.
#IQAI #stockpick
Numbers are end of June..
Cash 90k
Income 282k
Profit 278k
Costs 578k (Admin 572k, Finance 5k etc)
Loss 300k
Cash used in operations is 224k.
More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients.
It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023. Plus we now have the GE health care network to sell into. GE Health has installed 4 million scanners and other medical devices worldwide. GEHC total assets $28bil. They invest over $1bil annually in R&D. 259k patients supported daily using imaging technology. 2bil patients scanned annually.
Lots to look forward to in regards to upcoming updates
#IQAI On Friday afternoon announced a deal for IB Neuro and IB Delta T1 to be embedded in GE HealthCare's (GEHC) MR Smart Subscription. IB Neuro and IB Delta T1 maps are applications that accept magnetic resonance imaging (MRI) data as input and automatically compute quantitative and proprietary images as output.
The global MRI market is projected to grow at a rate of 7% and surpass $11 billion by 2030, and GEHC is a leading player in that market. A factor driving that growth are complementary advancements in imaging software, such as IB's quantitative solutions.
Their software is available via the newly launched Bayer Calantic platform.
They also have a drug in phase 1 but have already stated it will be entering phase 2 and this will be funded by a partnership with a major pharmaceutical company. They have recently received orphan drug status for this drug for both adult patients and children for the treatment of glioblastoma(brain cancer). They have recently announced they will be starting a second phase 1 study for children and have initiated discussions with several sites who have expressed a collaborative interest. Paediatric brain tumour research and development receive significant philanthropic funding. Consortiums of non-profits exist that help fund clinical trials for children, either partially or in their entirety. #IQAI have already made connections and introduced their progress to one organization. In turn, they identified several hospitals with whom they have established relationships so we should receive an update imminently for this. The ultimate objective of our program is to obtain regulatory approval for a medicine that could offer a positive impact on the length and quality of life for patients who otherwise have no other options. As the trial process continues, their efforts to identify and secure an accelerated regulatory approval pathway will also continue. Pathways, such as Fast Track Designation and Paediatric Rare Disease Priority Review Voucher (PRD-PRV), exist to expedite the development, review, and approval of promising drugs that treat diseases such as GBM and paediatric cancers.
Paediatric rare disease priority review vouchers have recently sold for over $100m with examples from Sarepta Therapeutics and bluebird bio both selling theirs to major pharmaceutical companies.
#IQAI Also have patented artificial intelligence ("AI") technology, IB Zero G generates enhanced "with contrast" images using only non-contrast (0% gadolinium) images as input. The FDA's response to the FDA 510(k) submission concluded that IB Zero G™ was too novel and unique a product and subsequently directed IB to pursue a different regulatory clearance pathway. IB is compiling additional documentation in preparation for a pre-submission meeting with the FDA and plans to submit a "de novo" application in the second half of the year. The de novo request is a market clearance pathway designed for novel medical devices for which n
Just rereading the report from this morning and this part stood out
“we are considering a phase 1 study in children and have initiated discussions with several sites who have expressed a collaborative interest. In addition, paediatric brain tumour research and development receive significant philanthropic funding. Consortiums of non-profits exist that help fund clinical trials for children, either partially or in their entirety. We have already made connections and introduced our progress to one organization. In turn, they identified several hospitals with whom they have established relationships.”
If you look at the top right corner of the poster titled Gallium Maltolate as Treatment for Pediatric Glioma it has the “macc fund” and “childrens hospital of Wisconsin could these be the organisations mentioned? Either way it shouldn’t be too much longer for an update on this if they have already started discussions
https://www.gallixa.com/GAMReferences/MolinoEtAl2019PedGlioma.pdf